This page features ACC's full coverage of the latest science from American Heart Association's (AHA) Scientific Sessions 2026.

Set your next event apart by welcoming your guests and attendees to The Conference Center at Heart House, located in the contemporary headquarters of the American College of Cardiology in Washington, ...

Reduced-dose non-vitamin K oral anticoagulants (NOACs) as well as aspirin alone were noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months ...

A new international expert consensus document refines and updates how heart failure is identified and classified, aiming to improve prevention, diagnosis and management of heart failure worldwide.

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

In patients with diabetes and multivessel coronary artery disease undergoing PCI, a ticagrelor-based dual antiplatelet therapy (DAPT) regimen did not offer the same level of benefit at preventing ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

Compared with placebo, PCSK9 inhibition with evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous myocardial infarction or ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study ...

In TAVI PCI, which was simultaneously published in NEJM, a strategy of TAVI before PCI was noninferior to a PCI-first strategy in patients with severe aortic stenosis and concomitant coronary artery ...